HeartBeam, Inc. (BEAT) shareholders
BEATNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31Also trades as BEATW
$0.55+0.01 (+2.06%)
Close on Oct 30, 2026Market cap $659.29KP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
8M
Shares held, 13F filers
Institutional holders
42
10 new, 6 sold out
Net institutional buying
3M
In Q2 2026
Insider trades, 12 months
9 buys · 3 sales
Net sold $126.09K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Strome Mark E Joint filing with Strome Group, Inc. (6.60%), Strome Investment Management LP (6.60%) and 1 more | 3,764,200 | 6.80% | 13D (active) amendment | Apr 16, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BEAT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 2,137,512 | – | $1.60M | +939,719 | 0.00% |
| BlackRock, Inc. | 987,837 | – | $740.88K | +89,516 | 0.00% |
| Corsair Capital Management, L.P. | 912,500 | – | $684.38K | New | 0.09% |
| Bleichroeder LP | 625,000 | – | $468.75K | New | 0.08% |
| Geode Capital Management, LLC | 479,386 | – | $359.59K | +102,174 | 0.00% |
| Smith, Salley & Associates | 367,647 | – | $275.74K | – | 0.01% |
| UBS Group AG | 298,917 | – | $224.19K | −36,272 | 0.00% |
| Vanguard Fiduciary Trust Co | 274,818 | – | $206.11K | +124,756 | 0.00% |
| Sigma Planning Corp | 247,700 | – | $185.78K | +115,150 | 0.00% |
| Beacon Pointe Advisors, LLC | 247,058 | – | $185.29K | −400 | 0.00% |
| O'Shaughnessy Asset Management, LLC | 208,191 | – | $156.14K | – | 0.00% |
| Ritholtz Wealth Management | 208,191 | – | $156.14K | – | 0.00% |
| Kestra Private Wealth Services, LLC | 173,439 | – | $130.08K | −500 | 0.00% |
| Raymond James Financial Inc | 134,434 | – | $100.83K | +28,484 | 0.00% |
| State Street Corp | 125,473 | – | $94.11K | – | 0.00% |
| Northern Trust Corp | 101,129 | – | $75.85K | +42,965 | 0.00% |
| Spectrum Asset Management, Inc. (NB/CA) | 100,400 | – | $75.30K | +6,000 | 0.02% |
| Cannon Financial Strategists, Inc. | 72,788 | – | $54.59K | – | 0.01% |
| Morgan Stanley | 57,045 | – | $42.78K | −1,554 | 0.00% |
| XTX Topco Ltd | 54,274 | – | $40.71K | +42,358 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 42 | 8M | 10 / 10 | 6 / 6 | 3M | 0M |
| Q1 2026 | 38 | 5M | 10 / 7 | 3 / 10 | 2M | 0M |
| Q4 2025 | 41 | 5M | 12 / 11 | 7 / 9 | 1M | 0M |
| Q3 2025 | 38 | 3M | 5 / 6 | 6 / 7 | 0M | 0M |
| Q2 2025 | 40 | 4M | 7 / 8 | 5 / 2 | 1M | 0M |
| Q1 2025 | 35 | 3M | 4 / 10 | 5 / 2 | 0M | 0M |
| Q4 2024 | 33 | 3M | 5 / 9 | 2 / 4 | 0M | 0M |
| Q3 2024 | 32 | 3M | 6 / 7 | 2 / 3 | 0M | 0M |
| Q2 2024 | 30 | 2M | 5 / 7 | 5 / 3 | 0M | 0M |
| Q1 2024 | 28 | 2M | 0 / 8 | 6 / 5 | 0M | 0M |
| Q4 2023 | 33 | 2M | 5 / 7 | 3 / 0 | 0M | 0M |
| Q3 2023 | 28 | 2M | 2 / 4 | 8 / 2 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
11 funds held BEAT in Q2 2026, 87% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of BEAT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,448,402 | – | $1.09M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 656,120 | – | $492.09K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 178,950 | – | $156.58K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 155,600 | – | $116.70K | 0.01% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 47,501 | – | $41.56K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 44,849 | – | $39.24K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 32,990 | – | $24.74K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 24,817 | – | $21.71K | 0.00% | May 31, 2026 |
| 1290 VT Micro Cap Portfolio | 10,462 | – | $7.85K | 0.00% | Jun 30, 2026 |
| Total Stock Market Index Trust | 1,199 | – | $899 | 0.00% | Jun 30, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -3,000 | – | -$2.25K | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Branislav Vajdic | President, Director | 3,970,784 | Jul 24, 2026 |
| Tim Cruickshank | CFO | 239,990 | Jul 24, 2026 |
| Kenneth Harry Persen | Chief Technology Officer | 448,290 | Jul 24, 2026 |
| Robert Paul ENO | President | 36,742 | Apr 16, 2026 |
| Richard Ferrari | Director | 352,289 | Apr 24, 2026 |
| Michael R. Jaff | Director | 127,059 | Apr 16, 2026 |
| Marga Ortigas-Wedekind | Director | 154,117 | Apr 16, 2026 |
| Mark E. Strome | Director | 3,707,146 | Apr 16, 2026 |
| Willem Elfrink | Director | 645,492 | Apr 16, 2026 |
| Kenneth Warwick Nelson III | Director | 144,388 | Mar 23, 2026 |
| Urioste George de | Director | 0 | Mar 23, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Tim Cruickshank CFO | Jul 24, 2026 | Award | +167,760 | – | – | 239,990 |
| Kenneth Harry Persen Chief Technology Officer | Jul 24, 2026 | Award | +105,740 | – | – | 448,290 |
| Branislav Vajdic President, Director | Jul 24, 2026 | Award | +260,870 | – | – | 3,970,784 |
| Branislav Vajdic President, Director | Jun 15, 2026 | Award | +2,800,000 | – | – | 3,709,914 |
| Richard Ferrari Director | Apr 16, 2026 | Buy | +57,500 | $0.80 | $46.00K | 286,636 |
| Richard Ferrari Director | Apr 16, 2026 | Buy | +62,500 | $0.80 | $50.00K | 291,636 |
| Tim Cruickshank CFO | Apr 16, 2026 | Buy | +31,250 | $0.80 | $25.00K | 72,230 |
| Branislav Vajdic Director | Apr 16, 2026 | Buy | +31,250 | $0.80 | $25.00K | 909,914 |
| Marga Ortigas-Wedekind Director | Apr 16, 2026 | Buy | +25,000 | $0.80 | $20.00K | 137,293 |
| Willem Elfrink Director | Apr 16, 2026 | Buy | +187,500 | $0.80 | $150.00K | 538,667 |
| Mark E. Strome Director | Apr 16, 2026 | Buy | +750,000 | $0.80 | $600.00K | 3,650,000 |
| Robert Paul ENO President | Apr 16, 2026 | Buy | +12,500 | $0.80 | $10.00K | 36,742 |
| Michael R. Jaff Director | Apr 16, 2026 | Buy | +31,250 | $0.80 | $25.00K | 31,250 |
| Michael R. Jaff Director | Feb 9, 2026 | Award | +20,689 | – | – | 95,809 |
| Kenneth Warwick Nelson III Director | Feb 9, 2026 | Award | +17,241 | – | – | 144,388 |
| Richard Ferrari Director | Feb 9, 2026 | Award | +50,000 | – | – | 229,136 |
| Urioste George de Director | Dec 18, 2025 | Sale | −33,185 | $2.83 | $93.91K | 0 |
| Mark E. Strome 10% owner | Dec 17, 2025 | Sale | −250,000 | $3.58 | $895.00K | 2,900,000 |
| Urioste George de Director | Dec 17, 2025 | Sale | −23,961 | $3.68 | $88.18K | 33,185 |
| Richard Ferrari Director | Feb 14, 2025 | Buy | +29,412 | $1.70 | $50.00K | 179,136 |
| Tim Cruickshank CFO | Feb 14, 2025 | Buy | +17,647 | $1.70 | $30.00K | 17,647 |
| Urioste George de Director | Sep 6, 2024 | Sale | −1,674 | $2.34 | $3.92K | 57,146 |
| Urioste George de Director | Aug 30, 2024 | Sale | −5,500 | $2.31 | $12.71K | 58,820 |
| Urioste George de Director | Aug 27, 2024 | Sale | −2,194 | $2.26 | $4.96K | 64,320 |
| Urioste George de Director | Aug 26, 2024 | Sale | −300 | $2.38 | $714 | 66,514 |
| Urioste George de Director | Aug 23, 2024 | Sale | −2,500 | $2.30 | $5.75K | 66,814 |
| Michael R. Jaff Director | Jun 12, 2024 | Award | +33,185 | – | – | 75,120 |
| Willem Elfrink Director | Jun 12, 2024 | Award | +33,185 | – | – | 317,982 |
| Urioste George de Director | Jun 12, 2024 | Award | +33,185 | – | – | 69,314 |
| Richard Ferrari Director | Jun 12, 2024 | Award | +44,247 | – | – | 149,724 |
| Kenneth Warwick Nelson III Director | Jun 12, 2024 | Award | +33,185 | – | – | 127,147 |
| Mark E. Strome 10% owner | Jun 12, 2024 | Award | +33,185 | – | – | 57,146 |
| Marga Ortigas-Wedekind Director | Jun 12, 2024 | Award | +33,185 | – | – | 112,293 |
| Urioste George de Director | Sep 29, 2023 | Sale | −5,500 | $2.06 | $11.33K | 36,129 |
| Urioste George de Director | Sep 28, 2023 | Sale | −8,000 | $2.04 | $16.32K | 41,629 |
| Urioste George de Director | Sep 27, 2023 | Sale | −1,834 | $2.11 | $3.87K | 49,629 |
| Urioste George de Director | Sep 26, 2023 | Sale | −5,000 | $2.09 | $10.45K | 51,463 |
| Urioste George de Director | Sep 22, 2023 | Sale | −2,393 | $2.21 | $5.29K | 56,463 |
| Urioste George de Director | Sep 21, 2023 | Sale | −100 | $2.41 | $241 | 58,856 |
| Urioste George de Director | Sep 20, 2023 | Sale | −883 | $2.46 | $2.17K | 58,956 |
| Urioste George de Director | Sep 18, 2023 | Sale | −5,000 | $2.46 | $12.30K | 59,839 |
| Urioste George de Director | Sep 15, 2023 | Sale | −4,269 | $2.43 | $10.37K | 64,839 |
| Urioste George de Director | Sep 14, 2023 | Sale | −5,000 | $2.17 | $10.85K | 69,108 |
| Urioste George de Director | Sep 13, 2023 | Sale | −3,122 | $1.95 | $6.09K | 74,108 |
| Urioste George de Director | Sep 13, 2023 | Sale | −1,878 | $1.90 | $3.57K | 77,230 |
| Willem Elfrink Director | Jul 13, 2023 | Award | +23,961 | – | – | 284,797 |
| Richard Ferrari Director | Jul 13, 2023 | Award | +31,948 | – | – | 105,477 |
| Mark E. Strome 10% owner | Jul 13, 2023 | Award | +23,961 | – | – | 23,961 |
| Urioste George de Director | Jul 13, 2023 | Award | +23,961 | – | – | 79,108 |
| Marga Ortigas-Wedekind Director | Jul 13, 2023 | Award | +23,961 | – | – | 79,108 |
| Kenneth Warwick Nelson III Director | Jul 13, 2023 | Award | +23,961 | – | – | 93,962 |
| Branislav Vajdic CHIEF EXECUTIVE OFFICER | Feb 10, 2023 | Option exercise | +1,287 | – | – | 911,391 |
| Richard Brounstein Chief Financial Officer | Feb 10, 2023 | Option exercise | +184 | – | – | 112,108 |
| Willem Elfrink Director | Feb 9, 2023 | Conversion | +3,640 | $2.75 | $10.01K | 316,150 |
| Willem Elfrink Director | Feb 9, 2023 | Returned to company | −125,351 | – | – | 312,510 |
| Richard Brounstein Chief Financial Officer | Dec 2, 2022 | Option exercise | +760 | – | – | 111,924 |
| Richard Brounstein Chief Financial Officer | Nov 2, 2022 | Option exercise | +759 | – | – | 111,164 |
| Richard Brounstein Chief Financial Officer | Oct 2, 2022 | Option exercise | +760 | – | – | 110,405 |
| Richard Brounstein Chief Financial Officer | Sep 2, 2022 | Option exercise | +757 | – | – | 109,645 |
| Richard Brounstein Chief Financial Officer | Aug 1, 2022 | Option exercise | +757 | – | – | 108,888 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 15, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
2M shares short
Days to cover
1.0
At 40M shares a day
Change since last report
-0.4%
From 2M shares
Short volume, 20 days
56.8%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of HeartBeam's stock actually held short. Settlement fails (shares not delivered on time) peaked at 17,759 shares on Aug 26, 2026 over the last 90 days.